(19) World Intellectual Property **Organization**

International Bureau



(43) International Publication Date 21 July 2005 (21.07.2005)

(10) International Publication Number WO 2005/066163 A3

- (51) International Patent Classification⁷: C07D 409/12, 453/02, 333/38, 409/14, 413/12, 413/14, 417/14, A61K 31/41, 31/40, 31/435, 31/495, 31/55, A61P 35/00
- (21) International Application Number:

PCT/GB2004/005400

(22) International Filing Date:

24 December 2004 (24.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/534,310 60/553,305

5 January 2004 (05.01.2004) US 15 March 2004 (15.03.2004)

- (71) Applicant (for all designated States except MG, US): AS-TRAZENECA AB [SE/SE]; S-SE-151 85 Sodertalje (SE).
- (71) Applicant (for MG only): ASTRAZENECA UK LIM-ITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ASHWELL, Susan [GB/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). GERO, Thomas [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). IOANNIDIS, Stephanos [GR/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). JANETKA, James [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). LYNE, Paul [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). SU, Mei [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). TOADER, Dorin [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts

02451 (US). YU, Dingwei [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). YU, Yan [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-SE-151 85 Sodertalje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 1 September 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS

$$\mathbb{R}^1$$
 \mathbb{R}^2 (1)

(57) Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

